Sarepta Therapeutics is an up-and-coming biotechnology company on a mission to provide effective therapies to treat 100% of children with Duchenne muscular dystrophy, a rare, universally fatal disease that affects young boys, robbing them of their childhood and shortening their life expectancy. This website was commissioned by the company as a turnkey project to introduce exciting early data around their gene therapy development programs for micro-dystrophin and GALGT2 to investors and the DMD community.